Multiple Sclerosis

• Breakdown of blood-brain barrier (BBB) and leukocyte infiltration: Under inflammatory conditions, activated T cells and B cells upregulate adhesion molecules (particularly α4-integrin) that interact with vascular cell adhesion molecule-1 (VCAM-1) on CNS endothelial cells. This interaction facilitates transendothelial migration across the BBB, which is further compromised by secretion of matrix metalloproteinases (MMP-2 and MMP-9) by infiltrating leukocytes. Disruption of tight junction proteins (claudins, occludin, zonula occludens-1) permits entry of autoreactive lymphocytes, macrophages, and plasma cells into the CNS parenchyma. This initial breach of BBB integrity may be preceded by molecular mimicry, wherein viral or bacterial antigens structurally resemble myelin epitopes (such as myelin oligodendrocyte glycoprotein [MOG] or myelin basic protein [MBP]), triggering cross-reactive T cell responses.

• Demyelination and axonal pathology: Infiltrating CD8+ and CD4+ T cells recognize myelin antigens presented on MHC class I and II molecules, respectively. Activated macrophages phagocytose myelin directly, and autoreactive B cells differentiate into plasma cells that produce anti-myelin antibodies (including anti-MOG and anti-myelin-associated glycoprotein [MAG] antibodies) contributing to antibody-dependent cellular cytotoxicity. The result is segmental demyelination—loss of myelin sheaths while axons remain initially intact—distinguishing MS from primary axonopathies. In acute lesions (active plaques), myelin loss exposes axonal membrane, causing conduction block and clinical symptoms. However, with progression and repeated inflammation, particularly in secondary progressive MS, primary axonal degeneration occurs through complement-mediated damage (via membrane attack complex formation), mitochondrial dysfunction in stressed axons, and loss of trophic support from oligodendrocytes. This transition from demyelination to neurodegeneration defines the shift from reversible to irreversible disability.

• Remyelination failure and chronic neurodegeneration: While oligodendrocyte progenitor cells (OPCs) are recruited to demyelinated lesions and can differentiate into mature oligodendrocytes capable of remyelination, this process is increasingly impaired with repeated inflammation, aging, and transition to progressive disease. Chronic lesions show reduced oligodendrocyte density, accumulated axonal iron, mitochondrial abnormalities, and persistent microglial activation even in the absence of active leukocyte infiltration. Neuroinflammatory mediators including TNF-α, IL-6, and IL-17 perpetuate microglial activation and oxidative stress, driving axonal degeneration independent of new demyelination. Gray matter pathology, including cortical demyelination and neuronal loss, contributes significantly to cognitive dysfunction and progressive disability but is less dependent on active inflammation. This pathophysiologic transition explains the clinical evolution from relapsing-remitting disease (reversible demyelination with intact axons) to secondary progressive MS (irreversible neurodegeneration).

• T cell dysfunction and loss of immune regulation: Central to MS pathogenesis is failure of regulatory T cells (Tregs) to suppress autoreactive effector T cells. Tregs normally maintain immune tolerance through production of IL-10 and TGF-β and by direct contact-dependent suppression. MS patients demonstrate reduced Treg numbers, impaired suppressive function, and altered differentiation from naive precursors. Simultaneously, there is expansion of pathogenic Th1 and Th17 cells producing IFN-γ and IL-17, respectively, both potent pro-inflammatory cytokines that enhance BBB permeability and recruit additional inflammatory cells. Dysregulation of IL-23 and IL-12 signaling pathways, which promote Th17 differentiation, has been implicated in MS susceptibility. Environmental factors such as vitamin D deficiency, prior viral infections (particularly Epstein-Barr virus), and altered microbiome composition modify this balance, shifting immune tolerance toward autoimmunity.

• Genetic susceptibility and HLA associations: MS shows strong genetic predisposition, with identical twin concordance of approximately 30% and sibling recurrence risk of 2-3%. The strongest genetic association is with HLA class II alleles, particularly HLA-DRB1*15:01 and HLA-DQA1*01 and DQB1*05:01, which are present in 50-60% of MS patients compared to 20-30% of controls. These HLA molecules present specific myelin peptides to T cells with high affinity, promoting autoreactive T cell activation. Conversely, HLA-A*02:01 is protective, likely due to presentation of myelin epitopes in a manner that induces regulatory responses. Genome-wide association studies (GWAS) have identified over 200 independent genetic variants associated with MS susceptibility, most enriched in immune-related genes (IL2RA, IL7R, TNF, ICAM1). However, genetic factors account for only 30-40% of MS heritability; environmental triggers are essential for disease manifestation, explaining the low penetrance of MS-associated genes and the higher discordance in monozygotic twins.

• Genetic factors and HLA alleles: Individuals carrying HLA-DRB1*15:01 have 2-3 fold increased MS risk compared to non-carriers. Other associated alleles (HLA-A*02:01, non-HLA susceptibility loci) modulate risk. Family history conveys 15-20% increased recurrence risk in first-degree relatives, though environmental influences on family members confound pure genetic penetrance. The genetic contribution is necessary but not sufficient for disease development, as concordance in monozygotic twins is only 30%.

• Epstein-Barr virus (EBV) infection: Strong epidemiological association exists between prior EBV infection and MS development. Nearly 100% of MS patients have serologic evidence of prior EBV infection, compared to 90-95% of age-matched controls, but the risk is substantially elevated in EBV-seronegative individuals who subsequently become infected during adolescence or adulthood. Cross-reactivity between EBV proteins (particularly EBNA-1) and myelin antigens (especially MOG) has been demonstrated, supporting a molecular mimicry hypothesis. Elevated anti-EBV antibody titers predict MS activity, suggesting ongoing viral-immune interactions in established disease.

• Vitamin D deficiency: Multiple observational studies demonstrate an inverse correlation between serum 25-hydroxyvitamin D levels and MS incidence and progression. Vitamin D insufficiency (<30 ng/mL) is associated with increased relapse rates and faster disability progression. Mechanistically, vitamin D promotes Treg differentiation and IL-10 production while suppressing Th1 and Th17 responses. Latitude gradients in MS prevalence (lower near equator) correlate with solar exposure and cutaneous vitamin D synthesis, though direct causation remains unproven in randomized trials.

• Smoking: Active and passive smoking increases MS risk 1.5-2 fold. Smoking impairs regulatory T cell function, increases oxidative stress, and may enhance BBB permeability. Smokers with MS demonstrate higher disease activity and faster progression to secondary progressive MS. Smoking cessation improves disease outcomes, making it a modifiable risk factor amenable to intervention.

• Obesity and metabolic factors: Childhood and adolescent obesity increases MS risk 2-fold. Elevated BMI correlates with higher inflammatory cytokine levels (IL-6, TNF-α) and reduced Treg frequencies. Metabolic endotoxemia (increased lipopolysaccharide-binding protein from altered microbiota) may promote Th17 differentiation and CNS inflammation in obese individuals.

• Environmental and infectious triggers: Beyond EBV, infections with other viruses (human herpesvirus-6, measles, paramyxoviruses) have been proposed as triggers, though evidence remains inconsistent. Helminths, conversely, may provide protection through enhanced Treg differentiation. Exposure to organic solvents, metals, and particulate matter has been associated with increased MS risk in occupational cohort studies. Oral contraceptive use increases MS risk by approximately 1.2-fold through immune modulation.

• Socioeconomic and lifestyle factors: Low socioeconomic status, high stress, and poor sleep quality correlate with increased MS incidence and relapse rates. These factors may operate through chronic stress-induced alterations in immune regulation and increased susceptibility to infections.

• Hygiene hypothesis: Geographic regions with improved sanitation show higher MS prevalence, consistent with the hygiene hypothesis. Reduced pathogenic and commensal microbial exposure in childhood may impair immune tolerance mechanisms, though this remains speculative.

• Optic neuritis (ON): Represents the most common initial symptom in MS, occurring in 15-20% of MS patients as first manifestation. Patients report subacute vision loss (hours to days) with orbital pain (90%), particularly with eye movements due to inflammatory involvement of the optic nerve. Visual symptoms include decreased acuity, dyschromatopsia (impaired color vision, particularly red desaturation), and visual field defects (often central scotoma). Afferent pupillary defect (Marcus Gunn pupil) is characteristic, reflecting asymmetric optic nerve dysfunction. Ophthalmoscopy may show normal appearance initially (retrobulbar neuritis) or swollen optic disc with flame hemorrhages (papillitis if anterior nerve involvement). Most ON episodes recover substantially within weeks, though some residual visual deficits may persist. Presence of brain MRI abnormalities at time of isolated ON predicts MS conversion (cumulative MS risk ~50% at 5 years if MRI abnormal, ~10% if normal).

• Sensory symptoms: Paresthesias and dysesthesias are among the most common symptoms, affecting 50% of MS patients at some point. Symptoms typically follow dermatomal or anatomically plausible distributions (e.g., one side of the body, one extremity). Lhermitte's sign—a characteristic electric shock sensation radiating from the neck down the spine with neck flexion—results from demyelination in the cervical spinal cord and is highly specific for MS (though not pathognomonic, occurring in other myelopathies). Sensory symptoms often precede motor findings and may result from dorsal column or spinothalamic tract demyelination. Numbness may be accompanied by positive phenomena (burning, tingling) reflecting abnormal firing in demyelinated axons (ectopic activity).

• Motor weakness and spasticity: Progressive weakness typically manifests as stiffness and difficulty with fine motor control before frank paralysis. Pyramidal signs—hyperreflexia, spasticity, extensor plantar responses (Babinski sign), and weakness predominantly affecting antigravity muscles—reflect corticospinal tract involvement common in MS. Lower extremity weakness is more common than upper extremity, often manifesting as difficulty climbing stairs, walking, or maintaining gait. Spasticity may develop insidiously, causing gait dysfunction, pain, and contractures. The clinical pattern of asymmetric, multi-focal weakness distinguishes MS from primary muscle disease or peripheral neuropathy. Fatigue—a subjective sense of exhaustion distinct from weakness—affects 70-80% of MS patients and may severely limit activities despite preserved strength testing.

• Cerebellar dysfunction: Affects 30-40% of MS patients, causing ataxia, dysarthria, and tremor. Intention tremor (tremor worsening as hand approaches target) and scanning speech (irregular, irregular rhythm with variable loudness) are characteristic. Dysdiadochokinesia (inability to perform rapid alternating movements), dysmetria, and gait ataxia reflect cerebellar and spinocerebellar tract demyelination. Cerebellar dysfunction may be one of the most disabling features, as it is often poorly responsive to current disease-modifying therapies.

• Brainstem involvement: Results in internuclear ophthalmoplegia (INO)—impaired adduction of one eye with nystagmus on abduction of the contralateral eye—from demyelination of the medial longitudinal fasciculus. Bilateral INO is virtually pathognomonic for MS in young patients (vs. unilateral INO in stroke in elderly). Other brainstem signs include vertigo (from vestibular nucleus involvement), facial weakness, trigeminal neuralgia, facial pain, and dysarthria. Vertical nystagmus or convergence-retraction nystagmus suggests midbrain involvement.

• Cognitive dysfunction and psychiatric symptoms: Cognitive impairment occurs in 40-70% of MS patients, manifesting as slowed processing speed, impaired working memory, attention deficits, and executive dysfunction. Cognitive decline correlates with MRI markers of disease burden (T2 lesion load, brain atrophy) rather than physical disability measures, reflecting independent pathologic processes. Depression affects 40-50% of MS patients (versus 15-20% of general population), arising from both neurobiological factors (inflammatory mediators, lesion location) and reactive responses to disability. Bipolar disorder is also overrepresented in MS. Anxiety disorders occur in 25% of patients.

• Bladder and bowel dysfunction: Urinary frequency and urgency (from detrusor hyperreflexia due to spinal cord involvement) occur in 50% of MS patients. Urinary retention (from detrusor-sphincter dyssynergia) predisposes to urinary tract infections. Constipation reflects decreased mobility and spinal involvement; fecal incontinence is less common. Erectile dysfunction occurs in 70% of male MS patients.

• Sexual dysfunction: Beyond erectile dysfunction, decreased libido and difficulty with orgasm are common, resulting from spinal cord involvement, fatigue, spasticity, and depression.

• Acute myelitis: Acute or subacute onset of paraplegia, paraparesis, or tetraparesis with sensory level and sphincter involvement indicates acute demyelinating transverse myelitis. The lesion may span multiple spinal cord segments (longitudinally extensive transverse myelitis, LETM, defined as ≥3 contiguous segments). Myelitic episodes often produce severe disability acutely but may recover substantially with high-dose corticosteroids and disease-modifying therapy.

• Clinically isolated syndrome (CIS): Defined as a single, acute CNS demyelinating event (e.g., isolated optic neuritis, brainstem syndrome, myelitis, or polysymptomatic presentation) in a previously neurologically normal patient. CIS may represent first manifestation of MS or may remain monophasic. Presence of asymptomatic brain MRI lesions and oligoclonal bands in cerebrospinal fluid (CSF) predicts progression to clinically definite MS; absence of these features carries lower conversion risk.

• Disease course variants: Relapsing-remitting MS (RRMS) comprises 85% of MS at onset and is characterized by discrete relapses (exacerbations, flare-ups) of new or worsening neurological symptoms lasting days to weeks, followed by complete or partial remission over weeks to months. Between relapses, patients may be neurologically stable or show slow progression. Secondary progressive MS (SPMS) develops in 50% of RRMS patients by 10 years if untreated; it is characterized by steady, progressive accumulation of disability with or without superimposed relapses. Primary progressive MS (PPMS), comprising 10-15% of cases, shows progressive disability from onset without distinct relapses. PPMS

Initial and definitive imaging

• MRI brain and spinal cord with and without gadolinium: the single best next step in suspected MS. Ovoid T2/FLAIR hyperintensities are periventricular, cortical/juxtacortical, infratentorial, and spinal cord in distribution; perivenular lesions radiating perpendicular from the corpus callosum are Dawson fingers.
• Gadolinium enhancement marks BBB breakdown in lesions roughly a month old or less; enhancing and non-enhancing lesions on the same scan establish DIT without waiting for a second study.

2017 McDonald criteria (International Panel/MAGNIMS)

• DIS: ≥1 T2 lesion in ≥2 of the four characteristic CNS locations listed above.
• DIT: a new T2 or enhancing lesion on follow-up MRI, or simultaneous enhancing and non-enhancing lesions, or CSF-specific oligoclonal bands, which the 2017 revision permits as a substitute for DIT in a patient with a clinically isolated syndrome.

Supporting studies

• Lumbar puncture: paired CSF/serum electrophoresis showing ≥2 oligoclonal bands in CSF but not serum, plus an elevated IgG index. Pleocytosis is mild and lymphocytic; a markedly elevated cell count or protein should redirect you to infection, sarcoidosis, or NMOSD.
• Visual evoked potentials: delayed P100 latency with preserved waveform indicates prior subclinical optic nerve demyelination.
• Mimic exclusion before committing to MS: serum AQP4-IgG (NMOSD) and MOG-IgG, B12, TSH, HIV, RPR, ANA, ACE, and Lyme serology in endemic areas. AQP4 seropositivity changes therapy entirely.

Acute relapse (disabling symptoms only)

• High-dose corticosteroids: IV methylprednisolone 1000 mg daily for 3–5 days (high-dose oral prednisone is bioequivalent). Steroids accelerate recovery by restoring BBB integrity and quenching inflammation but do not change long-term disability — a point examiners test.
• Plasma exchange: for severe, steroid-refractory relapse; the American Academy of Neurology (AAN) guideline on plasmapheresis in neurologic disease supports PLEX in fulminant demyelinating attacks. Rule out infection-driven pseudorelapse (Uhthoff phenomenon) before treating — treat the fever, not with steroids.

• Moderate-efficacy platform agents: interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate.
• Sphingosine-1-phosphate receptor modulators: fingolimod, siponimod — sequester lymphocytes in lymph nodes.
• High-efficacy escalation: anti-CD20 monoclonals (ocrelizumab, ofatumumab), natalizumab (anti-α4-integrin, blocks VLA-4/VCAM-1 diapedesis), alemtuzumab (anti-CD52), cladribine.
• Primary progressive MS: ocrelizumab is the only FDA-approved DMT. Active secondary progressive MS: siponimod.

Symptomatic management

• Spasticity: baclofen or tizanidine; fatigue: amantadine or modafinil; walking speed: dalfampridine (K⁺-channel blocker, lowers seizure threshold); neurogenic bladder: antimuscarinics with post-void residual monitoring; trigeminal neuralgia: carbamazepine; depression: SSRIs.

Contraindicated / cautioned

• TNF-α inhibitors — paradoxically worsen demyelination.
• Teriflunomide — teratogenic; requires cholestyramine washout.
• Natalizumab in JCV-antibody–positive patients — PML risk.
• S1P modulators with high-grade AV block, recent ACS, or prolonged QTc; screen for VZV immunity and obtain baseline OCT.
• Live vaccines during anti-CD20 or S1P therapy; screen HBV before anti-CD20.

Disease-related

• Neurogenic bladder with detrusor–sphincter dyssynergia: incomplete emptying → recurrent UTI, hydronephrosis, and urosepsis (emergency). Signaled by rising post-void residual and febrile UTI.
• High cervical cord or brainstem demyelination: diaphragmatic weakness or bulbar dysfunction → aspiration and neuromuscular respiratory failure (emergency); a falling vital capacity, not oxygen saturation, is the warning sign.
• Immobility complications: pressure ulcers, VTE, contractures from untreated spasticity, and osteoporosis compounded by repeated steroid courses.
• Depression with elevated suicide risk — MS carries a suicide rate above the general population; screen at every visit.
• Tumefactive demyelination: a large lesion with incomplete open-ring enhancement that mimics glioma or abscess; the ring opens toward the gray matter.
• Marburg variant: fulminant, rapidly fatal demyelination (emergency).

Treatment-related

• Progressive multifocal leukoencephalopathy (PML) with natalizumab: JC virus reactivation in oligodendrocytes. Risk rises with JCV seropositivity, prior immunosuppression, and longer treatment duration. Signals: subacute cognitive, visual, or motor decline with non-enhancing, ill-defined subcortical U-fiber lesions on MRI. This is an emergency — stop the drug, obtain CSF JCV PCR, and anticipate immune reconstitution inflammatory syndrome after plasma exchange.
• Alemtuzumab secondary autoimmunity: ITP, anti-GBM/Goodpasture disease, and autoimmune thyroid disease appear years later during immune reconstitution; monthly CBC, creatinine, and urinalysis are mandated. ITP with bleeding and anti-GBM with hematuria/rising creatinine are emergencies.
• Fingolimod/S1P modulators: first-dose bradycardia and AV block, macular edema, and VZV reactivation.
• Anti-CD20 agents: hypogammaglobulinemia, infusion reactions, and hepatitis B reactivation.
• Mitoxantrone (rarely used): dose-dependent cardiomyopathy and treatment-related AML.
• Corticosteroids: hyperglycemia, steroid psychosis, and avascular necrosis of the femoral head.

• Best next step in suspected MS is MRI brain and cord with gadolinium, not lumbar puncture. LP is a supportive study; CSF-specific oligoclonal bands can substitute for dissemination in time under the 2017 McDonald criteria.
• Oligoclonal bands must be CSF-specific: bands present in both CSF and serum reflect systemic inflammation, not intrathecal synthesis. Paired samples are always run.
• Bilateral internuclear ophthalmoplegia in a young woman is MS until proven otherwise; unilateral INO in an elderly patient is a pontine lacunar stroke.
• Buzzwords: Dawson fingers (perpendicular periventricular lesions), Lhermitte sign (cervical cord), Uhthoff phenomenon (heat-induced transient worsening), Marcus Gunn pupil, and Charcot's triad of nystagmus, intention tremor, and scanning speech.
• Uhthoff/pseudorelapse is not a true relapse. Hot shower, exercise, or fever transiently unmasks conduction block in demyelinated axons. Cool the patient and treat the infection — steroids are the wrong answer.
• The distractor to avoid is NMOSD. Longitudinally extensive transverse myelitis spanning ≥3 vertebral segments, severe bilateral optic neuritis, or intractable hiccups/vomiting (area postrema syndrome) should trigger AQP4-IgG testing. Interferon beta and natalizumab can worsen NMOSD, so the diagnosis changes management completely.
• Trigeminal neuralgia in a patient under 40 should raise suspicion for a pontine demyelinating plaque.
• Pregnancy: relapse rate falls in the third trimester and rebounds in the early postpartum period. All ACE inhibitors and teriflunomide are contraindicated in pregnancy; teriflunomide requires cholestyramine-accelerated elimination before conception.
• Ocrelizumab is the association examiners test for primary progressive MS — the only FDA-approved therapy for that phenotype.